
Eagle Pharmaceuticals EGRX
Quarterly report 2023-Q2
added 08-08-2023
Eagle Pharmaceuticals Shares 2011-2025 | EGRX
Annual Shares Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.9 M | 13.1 M | 13.5 M | 13.8 M | 14.8 M | 15.1 M | 15.5 M | 15.3 M | 9.96 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.5 M | 9.96 M | 13.8 M |
Quarterly Shares Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.1 M | 13.1 M | - | 13.2 M | 12.8 M | 12.7 M | - | 13.1 M | 13.1 M | 13.1 M | - | 13.5 M | 13.7 M | 13.7 M | - | 13.7 M | 13.8 M | 13.9 M | - | 15 M | 14.9 M | 14.8 M | 14.8 M | 15 M | 15.2 M | 15.3 M | - | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 15.5 M | 14.2 M | 14 M | 14 M | 14 M | 8.86 M | 3.05 M | 3.02 M | 3.05 M | 3.05 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.6 M | 3.02 M | 12.8 M |
Shares of other stocks in the Drug manufacturers industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
25.6 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
46.3 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
108 M | $ 1.16 | - | $ 125 M | ||
|
Cronos Group
CRON
|
350 M | $ 2.63 | - | $ 1.38 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
25.8 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
150 M | - | 0.86 % | $ 117 M | ||
|
Catalent
CTLT
|
181 M | - | - | $ 11.5 B | ||
|
Agile Therapeutics
AGRX
|
2.16 M | - | 10.11 % | $ 58.2 M | ||
|
DURECT Corporation
DRRX
|
26.3 M | - | - | $ 50.1 M | ||
|
Aurora Cannabis
ACB
|
169 M | $ 4.26 | - | $ 86.3 M | ||
|
Endo International plc
ENDP
|
235 M | - | - | $ 28.9 M | ||
|
Zomedica Corp.
ZOM
|
980 M | - | -0.21 % | $ 98 M | ||
|
Evoke Pharma
EVOK
|
3.34 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
50.8 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
127 M | - | 2.45 % | $ 38.1 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
42.7 M | - | - | $ 55.5 M | ||
|
Emergent BioSolutions
EBS
|
51.2 M | $ 12.16 | - | $ 623 M | ||
|
Athenex
ATNX
|
6.54 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
95.1 M | $ 21.54 | - | $ 2.05 B | ||
|
Evolus
EOLS
|
62 M | $ 6.67 | 0.15 % | $ 414 M | ||
|
Harrow Health
HROW
|
32.6 M | $ 50.02 | -1.46 % | $ 1.63 B | ||
|
OrganiGram Holdings
OGI
|
256 M | $ 1.7 | - | $ 402 M | ||
|
China Pharma Holdings
CPHI
|
17.5 M | $ 1.33 | - | $ 23.2 M | ||
|
Organogenesis Holdings
ORGO
|
132 M | $ 5.18 | - | $ 682 M | ||
|
Neoleukin Therapeutics
NLTX
|
492 K | - | - | $ 193 M | ||
|
Bausch Health Companies
BHC
|
365 M | $ 6.99 | - | $ 2.55 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
1.24 M | $ 3.62 | - | $ 4.49 M | ||
|
Lannett Company
LCI
|
40.4 M | - | 1.15 % | $ 7.11 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
14.1 M | $ 3.96 | - | $ 55.7 M | ||
|
Rockwell Medical
RMTI
|
23.3 M | $ 0.82 | - | $ 19.1 M | ||
|
Pacira BioSciences
PCRX
|
46.2 M | $ 26.07 | - | $ 1.21 B | ||
|
Sundial Growers
SNDL
|
1.86 M | $ 1.65 | - | $ 3.37 M | ||
|
Veru
VERU
|
135 M | $ 2.17 | - | $ 293 M | ||
|
PetIQ
PETQ
|
29.1 M | - | 1.64 % | $ 400 M | ||
|
Jupiter Wellness
JUPW
|
54.4 M | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
137 M | $ 13.94 | - | $ 1.92 B | ||
|
ProPhase Labs
PRPH
|
15.8 M | $ 0.45 | - | $ 7.13 M | ||
|
cbdMD
YCBD
|
4.31 M | $ 1.36 | - | $ 5.87 M | ||
|
Radius Health
RDUS
|
47.2 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
95.2 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
30.1 M | $ 4.53 | - | $ 136 M | ||
|
OptiNose
OPTN
|
112 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
71 M | $ 9.2 | - | $ 653 M | ||
|
PLx Pharma
PLXP
|
23.7 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
40.8 M | $ 5.7 | - | $ 233 M | ||
|
SCYNEXIS
SCYX
|
47.9 M | $ 0.61 | - | $ 29.2 M | ||
|
Tricida
TCDA
|
51.3 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
618 M | $ 9.02 | - | $ 5.57 B | ||
|
TherapeuticsMD
TXMD
|
10.4 M | $ 1.64 | - | $ 17.1 M |